Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital entered a deal to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group for 510 ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Investment firm Bain Capital said on Friday that it has signed an agreement to acquire Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group (OTCPK:MTLHY) for approximately 510 billion JPY (3.3 ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TOKYO -- Japan's Mitsubishi Chemical Group has granted a first-refusal right to U.S. investment fund Bain Capital for the purchase of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma ...

Mitsubishi Chemical Group is stepping up its efforts to streamline operations by entering negotiations with U.S. investment fund Bain Capital to sell its pharmaceutical arm, Mitsubishi Tanabe Pharma.

Experts have also previously warned that children may be particularly susceptible to smaller amounts of the chemical due to their lower bodyweight. In 2011 SCF established an acceptable daily ...

Mitsubishi Chemical Corporation had considered building the plant as early as 2016, but ultimately abandoned plans earlier this month after finding that demand wasn’t high enough to warrant the ...